You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Raw chart and full-history price indicators begin at the captured split on Jan 8, 2025; bars on opposite sides are not compared.
Jaxampal Pharmaceuticals Ltd. reported organic growth of 9.3%, H1 EBITDA margin of 22.9% and cash and bank balance of 135 crores. It targets Rs. 500 crore by FI 2028 and Q3 revenue crossing 100 crores with consolidated EBITDA margin above 22%.
Illustrative technical + ownership context — a signal mix, not investment advice.
Raw-price comparisons begin at the captured split on Jan 8, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XBOM:JAGSNPHARM | +1.0% | -1.6% | +3.4% | -0.4% | +11.9% |
Share classes and depositary receipts can have different prices and dividends.
| Ex-dividend date | Amount per share |
|---|---|
| 2026-09-04 | 4.00 INR |
| 2025-09-12 | 2.50 INR |
| 2024-09-06 | 2.00 INR |
| 2023-08-21 | 2.00 INR |
| 2021-10-29 | 1.60 INR |
| 2021-09-22 | 0.40 INR |
| 2020-09-22 | 0.20 INR |
| 2019-09-20 | 0.10 INR |
| 2018-09-18 | 0.04 INR |
| 2015-09-21 | 0.04 INR |
| 2014-09-25 | 0.20 INR |
| 2013-09-25 | 0.20 INR |
| 2012-09-21 | 0.20 INR |
| 2011-09-23 | 0.20 INR |
| 2010-09-21 | 0.20 INR |
No upcoming investor events are listed for this company yet.
